Market Cap
€1.1b
Last Updated
2020/11/27 18:53 UTC
Data Sources
Company Financials +
Executive Summary
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Overvalued with concerning outlook.
Similar Companies
Share Price & News
How has Biotest's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIO3 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BIO3's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
1.5%
BIO3
2.1%
DE Biotechs
1.4%
DE Market
1 Year Return
21.9%
BIO3
-7.1%
DE Biotechs
0.9%
DE Market
Return vs Industry: BIO3 exceeded the German Biotechs industry which returned -7.1% over the past year.
Return vs Market: BIO3 exceeded the German Market which returned 0.9% over the past year.
Shareholder returns
| BIO3 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | 2.1% | 1.4% |
| 30 Day | 0% | 2.9% | 8.7% |
| 90 Day | 2.3% | -7.4% | 2.3% |
| 1 Year | 22.2%21.9% | -7.0%-7.1% | 4.1%0.9% |
| 3 Year | 32.6%31.8% | 4.5%3.7% | 3.9%-5.1% |
| 5 Year | 79.8%77.8% | 49.7%48.1% | 24.8%7.1% |
Long-Term Price Volatility Vs. Market
How volatile is Biotest's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Biotest undervalued compared to its fair value and its price relative to the market?
2.3x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: BIO3 (€26.4) is trading above our estimate of fair value (€19.45)
Significantly Below Fair Value: BIO3 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BIO3 is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: BIO3 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIO3's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIO3 is good value based on its PB Ratio (2.3x) compared to the DE Biotechs industry average (3.7x).
Next Steps
Future Growth
How is Biotest forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
54.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIO3 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BIO3 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BIO3 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BIO3's revenue (8.7% per year) is forecast to grow faster than the German market (5.8% per year).
High Growth Revenue: BIO3's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIO3's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Biotest performed over the past 5 years?
-21.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIO3 is currently unprofitable.
Growing Profit Margin: BIO3 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIO3 is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.
Accelerating Growth: Unable to compare BIO3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIO3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).
Return on Equity
High ROE: BIO3 has a negative Return on Equity (-7.56%), as it is currently unprofitable.
Next Steps
Financial Health
How is Biotest's financial position?
Financial Position Analysis
Short Term Liabilities: BIO3's short term assets (€542.2M) exceed its short term liabilities (€103.3M).
Long Term Liabilities: BIO3's short term assets (€542.2M) do not cover its long term liabilities (€574.7M).
Debt to Equity History and Analysis
Debt Level: BIO3's debt to equity ratio (98.3%) is considered high.
Reducing Debt: BIO3's debt to equity ratio has increased from 87.1% to 98.3% over the past 5 years.
Debt Coverage: BIO3's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if BIO3's interest payments on its debt are well covered by EBIT.
Balance Sheet
Next Steps
Dividend
What is Biotest current dividend yield, its reliability and sustainability?
0.15%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BIO3's dividend (0.15%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.14%).
High Dividend: BIO3's dividend (0.15%) is low compared to the top 25% of dividend payers in the German market (3.66%).
Stability and Growth of Payments
Stable Dividend: BIO3 is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: BIO3 is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: BIO3 is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIO3's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.3yrs
Average management tenure
CEO
Michael Ramroth (59 yo)
1.5yrs
Tenure
€1,276,000
Compensation
Dr. Michael Ramroth serves as Chairman of the Management Board and CEO at Biotest Aktiengesellschaft since May 01, 2019. Dr. Ramroth serves as Chief Financial Officer at Biotest Aktiengesellschaft. He serv...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD1.53M) is about average for companies of similar size in the German market ($USD1.56M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Management Board | 1.5yrs | €1.28m | no data | |
| COO & Member of the Board of Management | 7.83yrs | €1.03m | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Head of Corporate HR | 5.25yrs | no data | no data | |
| Head of the Project Management Organisation | no data | no data | no data | |
| Head of Quality Operations | no data | no data | no data | |
| Head of Research & Development | no data | no data | no data | |
| Head of Development - Plasma Protein | no data | no data | no data | |
| Senior Vice President of Manufacturing | no data | no data | no data |
5.3yrs
Average Tenure
Experienced Management: BIO3's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Supervisory Board | 0.50yr | no data | no data | |
| Member of Supervisory Board | 10.58yrs | €44.00k | no data | |
| Chairman of the Supervisory Board | 3.25yrs | €135.00k | no data | |
| Member of Supervisory Board | 9.17yrs | €44.00k | no data | |
| Deputy Chairman of Supervisory Board | 2.67yrs | €72.00k | no data | |
| Member of Supervisory Board | 0.75yr | no data | no data |
3.0yrs
Average Tenure
61yo
Average Age
Experienced Board: BIO3's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Biotest Aktiengesellschaft's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Biotest Aktiengesellschaft
- Ticker: BIO3
- Exchange: XTRA
- Founded: 1946
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €1.053b
- Shares outstanding: 39.57m
- Website: https://www.biotest.com
Number of Employees
Location
- Biotest Aktiengesellschaft
- Landsteinerstrasse 5
- Dreieich
- Hessen
- 63303
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BIO3 | DB (Deutsche Boerse AG) | Yes | Preference Shares | DE | EUR | Jan 1992 |
| BIO3 | XTRA (XETRA Trading Platform) | Yes | Preference Shares | DE | EUR | Jan 1992 |
| 0N70 | LSE (London Stock Exchange) | Yes | Preference Shares | GB | EUR | Jan 1992 |
| BIES.F | OTCPK (Pink Sheets LLC) | Yes | Preference Shares | US | USD | Jan 1992 |
| BIO3D | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Preference Shares | GB | EUR | Jan 1992 |
| BIO3 | SWX (SIX Swiss Exchange) | Yes | Preference Shares | CH | CHF | Jan 1992 |
| BIO3 | WBAG (Wiener Boerse AG) | Yes | Preference Shares | AT | EUR | Jan 1992 |
| BIO | DB (Deutsche Boerse AG) | Ordinary Shares | DE | EUR | Jun 1996 | |
| BIO | XTRA (XETRA Trading Platform) | Ordinary Shares | DE | EUR | Jun 1996 | |
| 0N6Z | LSE (London Stock Exchange) | Ordinary Shares | GB | EUR | Jun 1996 | |
| BIOD | BATS-CHIXE (BATS 'Chi-X Europe') | Ordinary Shares | GB | EUR | Jun 1996 |
Biography
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Othe...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/11/27 18:53 |
| End of Day Share Price | 2020/11/27 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.